Harrell Investment Partners LLC Has $1.25 Million Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Harrell Investment Partners LLC boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 50.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,296 shares of the medical research company's stock after acquiring an additional 5,811 shares during the quarter. Harrell Investment Partners LLC's holdings in Edwards Lifesciences were worth $1,254,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $26,000. Vega Investment Solutions acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $27,000. Millstone Evans Group LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $29,000. Park Square Financial Group LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $44,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $54,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on EW. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Truist Financial reduced their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. Piper Sandler lifted their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. Citigroup reiterated a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $80.20.

Edwards Lifesciences Stock Up 0.9%

Shares of EW stock opened at $73.94 on Thursday. The stock's 50 day simple moving average is $74.85 and its 200 day simple moving average is $72.96. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. Edwards Lifesciences Corporation has a twelve month low of $58.93 and a twelve month high of $95.25. The company has a market capitalization of $43.37 billion, a price-to-earnings ratio of 10.56, a PEG ratio of 3.69 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The company's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.66 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the sale, the vice president now directly owns 47,206 shares in the company, valued at approximately $3,295,450.86. The trade was a 16.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total value of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,153,526.69. This represents a 27.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 51,898 shares of company stock valued at $3,796,154 in the last three months. Company insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.